Because viral clearance is compromised if HIV is allowed to replicate for an extended period of time—resulting in extensive damage to the immune system—controlling HIV with antiretroviral therapy may be critical to preventing this type of viral evolution in SARS-CoV-2 in patients with advanced HIV.
Despite significant medical advancements related to HIV treatment and quality of life, the risk of suicide in patients is high and health care providers should prioritize mental health screenings in this population.
Investigators have identified metabolic and glycomic signatures in blood samples of post-treatment controllers, a rare population of HIV-infected individuals who can naturally sustain viral suppression after antiretroviral therapy.
Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.
June 27 is National HIV Testing Day, so Pharmacy Times interviewed Warren O, a person living with HIV for 11 years who has first-hand experience with HIV stigma, on his perspective on the critical role of testing all sexually active individuals who may be at risk for HIV.
Investigators have found bNAbs for HIV, hepatitis C, and influenza, among others.
Pharmacists can implement several recommendations into their practice, regardless of the setting.
This reduction in white matter has been well-documented, but the exact mechanism of action has been unknown until now, according to the study authors.
Cabenuva, the first long-acting injectable for the treatment of HIV, is a 2-drug copackaged product containing cabotegravir and rilpivirine.
Warren O, a person living with HIV for 11 years who has first-hand experience with HIV stigma, discusses his perspective on how the reduction of stigma could help to end the HIV epidemic.
This group of antibodies is able to attach to the outer layer of HIV at a patch of glycans—chain-like structures of sugars that are on the surface of cells, including the outer shells of viruses.
Research could allow the study of long-term HIV infections and the testing of new curative therapies.
The researchers are hopeful this could eventually lead to the elimination of long-term antiretroviral treatment as a lifelong necessity for patients with HIV.
Final data from a phase 3 trial assessing evolocumab in patients with HIV who have high cholesterol confirmed the safety and efficacy of the drug as a treatment.
A combination immunotherapy of interleukin-21 (IL-21) and interferon alpha (IFN-alpha) in combination with antiretroviral therapy (ART) is effective in generating highly functional natural killer (NK) cells that can help control and reduce simian immunodeficiency virus (SIV) in animal models.
Certain pre-existing conditions are common among people living with HIV/AIDS, which may contribute to the severity of their COVID-19 cases.
HIV is currently not curable but can be controlled with effective treatment options to allow patients to live a healthy life with better quality.
The primary job of myeloid dendritic cells is to support T cells, which are key to the ability to control HIV infection.
Not all CD4+ T cells are equally susceptible to infection in vivo, which could suggest that the most susceptible cells could eventually become targets of preventive interventions.
Patient and provider organizations urge the Department of Health and Human Services and the Biden administration to enact policies and protections that improve prescription drug affordability for people in the United States.
Despite the fact that 98% of the survey respondents said they were aware of PrEP, less than 25% were currently taking it.
The molecules act as decoy CD4 proteins, which the HIV particles preferentially attach to instead of CD4 cells at the surface of the cell.
Among patients with HIV who had not been diagnosed with heart disease at the beginning of the study, the risk of developing heart disease, heart failure, or stroke for the first time was 90% higher among those taking beta-blockers.
Study is the first to examine how the choice of blood pressure medications influences the long-term risk of heart disease, stroke, and heart failure in a patient population with a higher risk of cardiovascular disease.
The research team analyzed CD4-cell gene expression data from a study of HIV-infected people in Africa and Asia.
